Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 16/20 | 0.57 |
| ▸ | ALOX5AP | P20292 | 15/20 | 0.57 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651589 | 0.86 | ALOX5AP (0.48) | FEN1ALOX5APPIM1PIM3PIM2 | |
| SCHEMBL4028337 | 0.82 | ALOX5AP (0.54) | FEN1ALOX5APPIM1NPC1RAB9A | |
| SCHEMBL2659628 | 0.79 | ALOX5AP (0.52) | FEN1ALOX5APPIM1PIM3PIM2 | |
| SCHEMBL5243501 | 0.79 | NPC1 (0.45) | FEN1ALOX5APPIM1PIM3PIM2 | |
| SCHEMBL25393299 | 0.76 | PLA2G7 (0.41) | FEN1ALOX5APPIM1 | |
| SCHEMBL30599164 | 0.76 | PLA2G7 (0.41) | FEN1ALOX5APPIM1 | |
| SCHEMBL21044560 | 0.76 | IMPDH2 (0.52) | FEN1ALOX5AP | |
| SCHEMBL21044588 | 0.76 | ALOX5AP (0.39) | FEN1ALOX5APPIM1PIM3PIM2 | |
| SCHEMBL16640380 | 0.74 | ALOX5AP (0.55) | FEN1ALOX5APPIM1NPC1RAB9A | |
| SCHEMBL31140243 | 0.74 | ALOX5AP (0.55) | FEN1ALOX5APPIM1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | FEN1 3571/4885ALOX5AP 4453/4885PIM1 2936/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | FEN1 2786/4885ALOX5AP 4072/4885PIM1 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.